Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: Agitation is a common, challenging symptom affecting large numbers of people with dementia and impacting on quality of life (QoL). There is an urgent need for evidence-based, cost-effective psychosocial interventions to improve these outcomes, particularly in the absence of safe, effective pharmacological therapies. This study aimed to evaluate the efficacy of a person-centred care and psychosocial intervention incorporating an antipsychotic review, WHELD, on QoL, agitation, and antipsychotic use in people with dementia living in nursing homes, and to determine its cost. METHODS AND FINDINGS: This was a randomised controlled cluster trial conducted between 1 January 2013 and 30 September 2015 that compared the WHELD intervention with treatment as usual (TAU) in people with dementia living in 69 UK nursing homes, using an intention to treat analysis. All nursing homes allocated to the intervention received staff training in person-centred care and social interaction and education regarding antipsychotic medications (antipsychotic review), followed by ongoing delivery through a care staff champion model. The primary outcome measure was QoL (DEMQOL-Proxy). Secondary outcomes were agitation (Cohen-Mansfield Agitation Inventory [CMAI]), neuropsychiatric symptoms (Neuropsychiatric Inventory-Nursing Home Version [NPI-NH]), antipsychotic use, global deterioration (Clinical Dementia Rating), mood (Cornell Scale for Depression in Dementia), unmet needs (Camberwell Assessment of Need for the Elderly), mortality, quality of interactions (Quality of Interactions Scale [QUIS]), pain (Abbey Pain Scale), and cost. Costs were calculated using cost function figures compared with usual costs. In all, 847 people were randomised to WHELD or TAU, of whom 553 completed the 9-month randomised controlled trial. The intervention conferred a statistically significant improvement in QoL (DEMQOL-Proxy Z score 2.82, p = 0.0042; mean difference 2.54, SEM 0.88; 95% CI 0.81, 4.28; Cohen's D effect size 0.24). There were also statistically significant benefits in agitation (CMAI Z score 2.68, p = 0.0076; mean difference 4.27, SEM 1.59; 95% CI -7.39, -1.15; Cohen's D 0.23) and overall neuropsychiatric symptoms (NPI-NH Z score 3.52, p < 0.001; mean difference 4.55, SEM 1.28; 95% CI -7.07,-2.02; Cohen's D 0.30). Benefits were greatest in people with moderately severe dementia. There was a statistically significant benefit in positive care interactions as measured by QUIS (19.7% increase, SEM 8.94; 95% CI 2.12, 37.16, p = 0.03; Cohen's D 0.55). There were no statistically significant differences between WHELD and TAU for the other outcomes. A sensitivity analysis using a pre-specified imputation model confirmed statistically significant benefits in DEMQOL-Proxy, CMAI, and NPI-NH outcomes with the WHELD intervention. Antipsychotic drug use was at a low stable level in both treatment groups, and the intervention did not reduce use. The WHELD intervention reduced cost compared to TAU, and the benefits achieved were therefore associated with a cost saving. The main limitation was that antipsychotic review was based on augmenting processes within care homes to trigger medical review and did not in this study involve proactive primary care education. An additional limitation was the inherent challenge of assessing QoL in this patient group. CONCLUSIONS: These findings suggest that the WHELD intervention confers benefits in terms of QoL, agitation, and neuropsychiatric symptoms, albeit with relatively small effect sizes, as well as cost saving in a model that can readily be implemented in nursing homes. Future work should consider how to facilitate sustainability of the intervention in this setting. TRIAL REGISTRATION: ISRCTN Registry ISRCTN62237498.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Since the 2017 Commission two new systematic reviews of antidepressants to treat depression in dementia reported moderate quality evidence that antidepressant treatment for people with dementia does not lead to better control of symptomatology compared with placebo.214, 215”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [214]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cornell scale for depression in dementia
Alexopoulos, G. S., Abrams, R. C., Young, R. C., & Shamoian, C. A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90038-8 · Cited by 2,678
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
A Description of Agitation in a Nursing Home
Cohen-mansfield, J., Marx, M. S., & Rosenthal, A. S. (1989) · Journal of Gerontology · doi:10.1093/geronj/44.3.m77 · Cited by 1,349 · cited 11×
“A sub-group analysis was also undertaken comparing the WHELD intervention in people with mild to moderate (FAST 4–5), moderately severe (FAST 6), and severe (FAST 7) dementia, focusing on the primary and key secondary outcomes (DEMQOL, CMAI, and NPI-NH).”
MethodInfluentialEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · cited 3×
“Benefits from pharmacological treatment with atypical antipsychotics are limited to modest improvements in aggression [12,13,15], and the significant advantage on the CMAI for the WHELD intervention compared to control is comparable to the modest treatment advantage for atypical antipsychotics from a meta-analysis of…”
BackgroundResultA Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia
Schneider, L. S., Pollock, V. E., & Lyness, S. A. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb02407.x · Cited by 650 · cited 1×
“The findings are particularly favourable when compared with those of trials of antipsychotic medications, which show only very modest benefits over 12 weeks in the context of significant harms [41,42].”
ResultBehavioral Treatment of Depression in Dementia Patients: A Controlled Clinical Trial
Teri, L., Logsdon, R. G., Uomoto, J., & McCurry, S. M. (1997) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/52b.4.p159 · Cited by 648 · cited 3×
“Elements of the WHELD intervention, such as social interaction and pleasant events, have previously been demonstrated to improve agitation in modest-sized RCTs [22,23].”
BackgroundLivingston, G., Johnston, K., Katona, C., Paton, J., Lyketsos, C. G., & Old Age Task Force of the World Federation of Biological Psychiatry (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.1996 · Cited by 591 · cited 3×
“Livingston and colleagues [22] in a comprehensive systematic review examined the benefits of a range of sensory, psychological, and behavioural interventions in the treatment of agitation.”
BackgroundEffect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · cited 2×
“Recent studies have begun to suggest that other pharmacological therapies such as citalopram [20] and dextromethorphan [21] may confer significant benefit for the treatment of agitation, but further studies are needed.”
BackgroundBallard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Self-citationChenoweth, L., King, M. T., Jeon, Y.-H., Brodaty, H., Stein-Parbury, J., Norman, R., Haas, M., & Luscombe, G. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70045-6 · Cited by 528 · cited 1×
“Our results also compare favourably to those of the small number of published intervention studies that have focused on promoting PCC, none of which have reported benefits in QoL [6,7].”
ResultFossey, J., Ballard, C., Juszczak, E., James, I., Alder, N., Jacoby, R., & Howard, R. (2006) · BMJ · doi:10.1136/bmj.38782.575868.7c · Cited by 512 · cited 1×
“Our results also compare favourably to those of the small number of published intervention studies that have focused on promoting PCC, none of which have reported benefits in QoL [6,7].”
ResultSelf-citationThe Abbey pain scale: a 1-minute numerical indicator for people with end-stage dementia
Abbey, J., Piller, N., Bellis, A. D., Esterman, A., Parker, D., Giles, L., & Lowcay, B. (2004) · International Journal of Palliative Nursing · doi:10.12968/ijpn.2004.10.1.12013 · Cited by 506 · cited 3×
“Secondary outcomes also included global deterioration (CDR) [26], mood (Cornell Scale for Depression in Dementia [CSSD]) [32], antipsychotic use, unmet needs (Camberwell Assessment of Need for the Elderly [CANE]) [33], quality of interactions (Quality of Interactions Scale [QUIS]) [34], pain (Abbey Pain Scale) [35], m…”
BackgroundInfluentialWood, S., Cummings, J. L., Hsu, M.-A., Barclay, T., Wheatley, M. V., Yarema, K. T., & Schnelle, J. F. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200002000-00010 · Cited by 489 · cited 10×
“A sub-group analysis was also undertaken comparing the WHELD intervention in people with mild to moderate (FAST 4–5), moderately severe (FAST 6), and severe (FAST 7) dementia, focusing on the primary and key secondary outcomes (DEMQOL, CMAI, and NPI-NH).”
MethodInfluentialManagement of agitation and aggression associated with Alzheimer disease
Ballard, C. G., Gauthier, S., Cummings, J. L., Brodaty, H., Grossberg, G. T., Robert, P., & Lyketsos, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.39 · Cited by 404 · cited 3×
“Benefits from pharmacological treatment with atypical antipsychotics are limited to modest improvements in aggression [12,13,15], and the significant advantage on the CMAI for the WHELD intervention compared to control is comparable to the modest treatment advantage for atypical antipsychotics from a meta-analysis of…”
BackgroundResultSelf-citationPrince, M. J., Prina, M. A., & Guerchet, M. (2009) · Cited by 383
Camberwell Assessment of Need for the Elderly (CANE): Development, validity and reliability
Reynolds, T., Thornicroft, G., Abas, M., Woods, B., Hoe, J., Leese, M., & Orrell, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.5.444 · Cited by 359
Self-citationNeuroleptic drugs in dementia: benefits and harm
Ballard, C., & Howard, R. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1926 · Cited by 308 · cited 3×
“Benefits from pharmacological treatment with atypical antipsychotics are limited to modest improvements in aggression [12,13,15], and the significant advantage on the CMAI for the WHELD intervention compared to control is comparable to the modest treatment advantage for atypical antipsychotics from a meta-analysis of…”
BackgroundResultSelf-citationCohen-Mansfield, J., Libin, A., & Marx, M. S. (2007) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/62.8.908 · Cited by 260 · cited 1×
“A parallel systematic review concentrating specifically on psychological and behavioural interventions identified 40 clinical trials in people with dementia, and, together with other key studies, highlights the potential value of enjoyable activities as a successful treatment approach for agitation [5,23,24].”
BackgroundBallard, C., Lana, M. M., Theodoulou, M., Douglas, S., McShane, R., Jacoby, R., Kossakowski, K., Yu, L.-M., Juszczak, E., & on behalf of the Investigators DART AD (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050076 · Cited by 233 · cited 1×
“The findings are particularly favourable when compared with those of trials of antipsychotic medications, which show only very modest benefits over 12 weeks in the context of significant harms [41,42].”
Self-citationCummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., et al. (2015) · JAMA · doi:10.1001/jama.2015.10214 · Cited by 209 · cited 2×
“Recent studies have begun to suggest that other pharmacological therapies such as citalopram [20] and dextromethorphan [21] may confer significant benefit for the treatment of agitation, but further studies are needed.”
BackgroundAuer, S., & Reisberg, B. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004869 · Cited by 208 · cited 5×
“A sub-group analysis was also undertaken comparing the WHELD intervention in people with mild to moderate (FAST 4–5), moderately severe (FAST 6), and severe (FAST 7) dementia, focusing on the primary and key secondary outcomes (DEMQOL, CMAI, and NPI-NH).”
MethodInfluentialDeterminants of Quality of Life in Nursing Home Residents with Dementia
Wetzels, R. B., Zuidema, S. U., de Jonghe, J. F. M., Verhey, F. R. J., & Koopmans, R. T. C. M. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000280437 · Cited by 178 · cited 1×
“Agitation is a frequent and distressing symptom for people with dementia living in nursing homes [10,11,40].”
BackgroundMulhern, B., Rowen, D., Brazier, J., Smith, S., Romeo, R., Tait, R., Watchurst, C., Chua, K.-C., Loftus, V, Young, T., et al. (2013) · Health Technology Assessment · doi:10.3310/hta17050 · Cited by 174 · cited 8×
“The same approach was used for the analysis of all secondary outcomes other than mortal- ity, antipsychotic use, QUIS, and cost, except that the respective baseline variables were used as covariates rather than baseline DEMQOL-Proxy.”
MethodInfluentialSelf-citationDean, R., Proudfoot, R., & Lindesay, J. E. B. (1993) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930081004 · Cited by 169 · cited 1×
“Secondary outcomes also included global deterioration (CDR) [26], mood (Cornell Scale for Depression in Dementia [CSSD]) [32], antipsychotic use, unmet needs (Camberwell Assessment of Need for the Elderly [CANE]) [33], quality of interactions (Quality of Interactions Scale [QUIS]) [34], pain (Abbey Pain Scale) [35], m…”
BackgroundTestad, I., Corbett, A., Aarsland, D., Lexow, K. O., Fossey, J., Woods, B., & Ballard, C. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214000131 · Cited by 164 · cited 3×
“Cost is a major consideration in the development and implementation of interventions in nursing homes [5,8,9].”
BackgroundSelf-citationBallard, C. G., Margallo-Lana, M., Fossey, J., Reichelt, K., Myint, P., Potkins, D., & O'Brien, J. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0810 · Cited by 161 · cited 2×
“Agitation is a frequent and distressing symptom for people with dementia living in nursing homes [10,11,40].”
BackgroundSelf-citationBallard, C., Orrell, M., YongZhong, S., Moniz-Cook, E., Stafford, J., Whittaker, R., Woods, B., Corbett, A., Garrod, L., Khan, Z., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15010130 · Cited by 142
Self-citationBallard, C., Creese, B., Corbett, A., & Aarsland, D. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.506711 · Cited by 139
Self-citationAgitation and aggression in people with Alzheimer's disease
Ballard, C., & Corbett, A. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835f414b · Cited by 128
Self-citationFossey, J., Masson, S., Stafford, J., Lawrence, V., Corbett, A., & Ballard, C. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4072 · Cited by 128 · cited 2×
“However, no significant benefits in improving QoL were achieved [8].”
BackgroundSelf-citationDementia care costs and outcomes: a systematic review
Knapp, M., Iemmi, V., & Romeo, R. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3864 · Cited by 126 · cited 4×
“Abbreviations: ANCOVA, analysis of covariance; CANE, Camberwell Assessment of Need for the Elderly; CDR, Clinical Dementia Rating; CMAI, Cohen-Mansfield Agitation Inventory; CSRI, Client Service Receipt Inventory; CSSD, Cornell Scale for Depression in Dementia; FAST, Functional Assessment Staging Tool; NPI-NH, Neurops…”
MethodInfluentialSelf-citationGeneralized method for adaptive randomization in clinical trials
Russell, D., Hoare, Z. S. J., Whitaker, R., Whitaker, C. J., & Russell, I. T. (2011) · Statistics in Medicine · doi:10.1002/sim.4175 · Cited by 121 · cited 1×
“Randomisation was performed by dynamic allocation [38] to protect against subversion while ensuring that the trial maintained a good balance to the allocation ratio of 1:1 both within each stratification variable and across the trial.”
MethodTreatment of Behavioral and Psychological Symptoms of Alzheimer’s Disease
Corbett, A., Smith, J., Creese, B., & Ballard, C. G. (2012) · Current Treatment Options in Neurology · doi:10.1007/s11940-012-0166-9 · Cited by 79 · cited 2×
“Agitation is a frequent and distressing symptom for people with dementia living in nursing homes [10,11,40].”
BackgroundSelf-citationCost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial
Romeo, R., Knapp, M., Hellier, J., Dewey, M., Ballard, C., Baldwin, R., Bentham, P., Burns, A., Fox, C., Holmes, C., et al. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.115212 · Cited by 52 · cited 4×
“Abbreviations: ANCOVA, analysis of covariance; CANE, Camberwell Assessment of Need for the Elderly; CDR, Clinical Dementia Rating; CMAI, Cohen-Mansfield Agitation Inventory; CSRI, Client Service Receipt Inventory; CSSD, Cornell Scale for Depression in Dementia; FAST, Functional Assessment Staging Tool; NPI-NH, Neurops…”
MethodInfluentialSelf-citationWhitaker, R., Fossey, J., Ballard, C. G., Orrell, M. W., Moniz-Cook, E. D., Woods, B. T., Murray, J., Stafford, J., Knapp, M. R. J., Romeo, R., et al. (2014) · Trials · doi:10.1186/1745-6215-15-284 · Cited by 37 · cited 2×
“Data analysis protocol for the RCT, as developed for this study and the associated factorial study [25].”
MethodSelf-citationPrescription of antipsychotics in people with dementia
Ballard, C., Corbett, A., & Howard, R. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.128710 · Cited by 27 · cited 1×
“Despite the close link of QoL to agitation and other neuropsychiatric symptoms, risk of falls, worsening cognition, and mortality, none of the 18 randomised controlled trials (RCTs) found in 2 systematic reviews of antipsychotic medication use in individuals with dementia measured QoL as an outcome [3,4].”
BackgroundSelf-citationBallard, C., Corbett, A., Orrell, M., et al. (2017) · Data Archiving and Networked Services (DANS) · doi:10.5061/dryad.75373
Self-citation
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
Self-citationRetractedDementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Economics and mental health: the current scenario
Knapp, M., & Wong, G. (2020) · World Psychiatry · doi:10.1002/wps.20692 · Cited by 409
“…incorporated antipsychotic review, showed benefits in both agitation and quality of life, suggestive of a cost-saving model even with a relatively small effect size 79 ; with the additional cost of the programme offset by the higher health and social care costs in the treatment as usual group 78 .”
Self-citationWhat is rehabilitation? An empirical investigation leading to an evidence-based description
Wade, D. T. (2020) · Clinical Rehabilitation · doi:10.1177/0269215520905112 · Cited by 314
“80,81 Finally, this person-centred approach has already been recognized in one definition of rehabilitation, adopted by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) 4”
D’Cunha, N. M., Nguyen, D., Naumovski, N., McKune, A. J., Kellett, J., Georgousopoulou, E. N., Frost, J., & Isbel, S. (2019) · Gerontology · doi:10.1159/000500040 · Cited by 217
Metadata
- Authors
- Ballard, C., Corbett, A., Orrell, M., Williams, G., Moniz-Cook, E., Romeo, R., Woods, B., Garrod, L., Testad, I., Woodward-Carlton, B., Wenborn, J., Knapp, M., & Fossey, J.
- Affiliations
- University of Exeter (GB)
- University of Nottingham (GB)
- King's College London (GB)
- University of Hull (GB)
- Bangor University (GB)
- Oxford Health NHS Foundation Trust (GB)
- University College London (GB)
- London School of Economics and Political Science (GB)
- Corresponding author
- Ballard, Clive
- ORCID
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-02-06
- Volume
- 15
- Issue
- 2
- Pages
- e1002500
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC5800565
- OpenAlex
- W2786082650
- Cited by
- 263
- References
- 42
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 29 · 2023: 30 · 2022: 39 · 2021: 36 · 2020: 30 · 2019: 20 · 2018: 10
- FWCI
- 18.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- London School of Economics and Political Science Research Online (London School of Economics and Political Science) (acceptedVersion)
- London School of Economics and Political Science Theses Online (London School of Economics and Political Science) (acceptedVersion)
- Repository@Hull (Worktribe) (University of Hull) (acceptedVersion, other-oa)
- Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
- Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Funders
- Programme Grants for Applied Research (RP-PG-0608-10133)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Geriatrics and Gerontology › Geriatric Care and Nursing Homes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative Care and End-of-Life Issues
- Keywords
- person-centred care, dementia, nursing homes, agitation, antipsychotic use, psychosocial interventions, employee training, quality of life, neuropsychiatric symptoms, quality of care, cost-effectiveness, unmet needs, pain, depression in dementia, mortality, interaction quality, DEMQOL
- MeSH terms
- Aged, 80 and over, Cost-Benefit Analysis, Dementia, Education, Nursing, Continuing, Female, United Kingdom, Homes for the Aged, Humans, Interpersonal Relations, Male, Nurse-Patient Relations, Nursing Homes, Psychomotor Agitation, Quality of Life, Antipsychotic Agents, Patient-Centered Care, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
